Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VICL (Vical Labs) -- Ignore unavailable to you. Want to Upgrade?

To: Pseudo Biologist who wrote (405)	10/24/1997 4:40:00 PM
From: dbuki	Read Replies (1) \| Respond to of 1972

Note that Vical's patent is for specific lipids which are listed and structurally dislosed. Vical must have concluded at that time that a structurally non-specific claim would be too broad and therefore unpatentable. This is one of the arguments on which the GeneMedicine patent will be challenged down the road.

To: Pseudo Biologist who wrote (405)	10/26/1997 11:26:00 AM
From: dbuki	Read Replies (1) \| Respond to of 1972

Some additional thoughts on the GeneMedicine/Vical patent issue. Since GeneMedicine received a simultaneus patent in Europe, it may very well be challenged there. There is, I believe, a 9-month period after issuance to contest validity. I seem to recall that Schering (Berlin), for example, successfully challenged Biogen's beta-interferon patent oversees. In the U.S. there is no infringement until commercialization occurs. Therefore, research can continue uniterrupted by the entities involved.